Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Merck 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

3Q Revenues: $6.1 billion (+12%)

3Q Earnings: $1.5 billion (+62%)

YTD Revenues: $18.0 billion (+8%)

YTD Earnings: $4.9 billion (+24%)

Comments: Singulair sales rose 17% to $1 billion. Diabetes treatment Januvia, launched in October 2006, posted $185 million in 3Q07 sales. Gardasil, the HPV vaccine approved in the U.S. in June 2006, posted worldwide sales of $418 million. Sales of Zetia and Vytorin are not recognized as revenues, but as equity from a joint venture. The cholesterol treatments products reached all-time highs in prescriptions in 3Q07, and posted combined sales of $1.3 billion (+26%), of which Merck recognizes approximately half.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters